Semaglutide injection for losing weight 5mg dosage drug
| Product name | Semaglutide |
| CAS No. | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.57754 |
| Purity | 99% |
| Appearance | White or almost white powder |
| Package | Aluminum Bag;Drums |
| Shelf life | 2 years |
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insuli n. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in Dec 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger,
food craving and body fat.
Semaglutide has a chemical structure that is very similar to the hormone glucagon-like peptide 1 (GLP-1), which regulates both
insuli n secretion and appetite. In December, the US Food and Drug Administration approved the semaglutide injection Ozempic as a once-weekly adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Semaglutide may help people with obesity lose weight. A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight, a new study suggests.
Semaglutide injection for losing weight 5mg dosage drug
| Product name | Semaglutide |
| CAS No. | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.57754 |
| Purity | 99% |
| Appearance | White or almost white powder |
| Package | Aluminum Bag;Drums |
| Shelf life | 2 years |
Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insuli n. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in Dec 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger,
food craving and body fat.
Semaglutide has a chemical structure that is very similar to the hormone glucagon-like peptide 1 (GLP-1), which regulates both
insuli n secretion and appetite. In December, the US Food and Drug Administration approved the semaglutide injection Ozempic as a once-weekly adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Semaglutide may help people with obesity lose weight. A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight, a new study suggests.
